{"id":"taltz","brandName":"Taltz","genericName":"Taltz","companyId":"yale-university","companyName":"Yale University","phase":"marketed","status":"approved","modality":"Small molecule","aliases":["Ixekizumab"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Taltz, also known as ixekizumab, is a humanized monoclonal antibody that binds and neutralizes interleukin 17A, reducing inflammation. It is used to treat autoimmune diseases, including psoriasis and psoriatic arthritis, as indicated by clinical trials registered on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":3,"mechanism":{"target":"Interleukin-17A"},"administration":{},"safety":{"commonSideEffects":[{"effect":"Adverse events (overall)","drugRate":"58%","severity":"common","organSystem":""},{"effect":"Infections","drugRate":"27%","severity":"common","organSystem":""},{"effect":"Injection site reactions","drugRate":"","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infections","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Tinea infections","drugRate":"","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"<1%","severity":"common","organSystem":""},{"effect":"Oral candidiasis","drugRate":"<1%","severity":"common","organSystem":""},{"effect":"Urticaria","drugRate":"<1%","severity":"common","organSystem":""},{"effect":"Influenza","drugRate":"<1%","severity":"common","organSystem":""},{"effect":"Conjunctivitis","drugRate":"<1%","severity":"common","organSystem":""},{"effect":"Inflammatory bowel disease","drugRate":"<1%","severity":"common","organSystem":""},{"effect":"Angioedema","drugRate":"<1%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Serious adverse events (overall 0-60 weeks)","drugRate":"3%","severity":"serious"},{"effect":"Serious adverse events (maintenance period)","drugRate":"4%","severity":"serious"},{"effect":"Serious infections","drugRate":"0.4%","severity":"serious"}]},"trials":[],"indications":{"approved":[{"name":"Ankylosing spondylitis","diseaseId":"ankylosing-spondylitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythrodermic psoriasis","diseaseId":"erythrodermic-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-radiographic axial spondyloarthritis","diseaseId":"non-radiographic-axial-spondyloarthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriatic arthritis","diseaseId":"psoriatic-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pustular psoriasis","diseaseId":"pustular-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT06945107","phase":"PHASE3","title":"A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2025-05-27","conditions":["Plaque Psoriasis"],"enrollment":308,"completionDate":"2027-01-19"},{"nctId":"NCT04527380","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":["Juvenile Psoriatic Arthritis","Enthesitis Related Arthritis"],"enrollment":101,"completionDate":"2028-04"},{"nctId":"NCT06857942","phase":"PHASE4","title":"A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-19","conditions":["Psoriasis","Overweight or Obesity"],"enrollment":200,"completionDate":"2028-05"},{"nctId":"NCT04340076","phase":"PHASE4","title":"Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-08-20","conditions":["Psoriasis","Psoriasis Vulgaris"],"enrollment":244,"completionDate":"2025-01-31"},{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":["Psoriasis"],"enrollment":15842,"completionDate":"2030-12-31"},{"nctId":"NCT06398106","phase":"PHASE4","title":"Proactive TDM Versus Standard Use of Biologics in Psoriasis","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2024-12-20","conditions":["Psoriasis Vulgaris"],"enrollment":210,"completionDate":"2028-03-01"},{"nctId":"NCT07443956","phase":"NA","title":"Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2026-02-24","conditions":["Psoriatic Arthritis (PsA)","Obesity & Overweight"],"enrollment":45,"completionDate":"2030-05"},{"nctId":"NCT06864026","phase":"PHASE4","title":"A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-06","conditions":["Psoriatic Arthritis","Overweight or Obesity"],"enrollment":200,"completionDate":"2027-11"},{"nctId":"NCT07386717","phase":"","title":"Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2024-01-01","conditions":["Psoriatic Arthritis","Upadacitinib","Interleukin-17 Inhibitors"],"enrollment":70,"completionDate":"2025-12-31"},{"nctId":"NCT05309616","phase":"PHASE2","title":"Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2025-02-20","conditions":["Idiopathic Subglottic Stenosis"],"enrollment":10,"completionDate":"2026-05"},{"nctId":"NCT06588296","phase":"PHASE3","title":"Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-24","conditions":["Psoriatic Arthritis","Obesity"],"enrollment":279,"completionDate":"2026-04"},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":["Psoriasis","Atopic Dermatitis"],"enrollment":10,"completionDate":"2030-06-01"},{"nctId":"NCT06588283","phase":"PHASE3","title":"Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-30","conditions":["Psoriasis","Obesity"],"enrollment":250,"completionDate":"2026-05"},{"nctId":"NCT07200986","phase":"PHASE1","title":"Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2025-09-17","conditions":["Healthy Participants"],"enrollment":218,"completionDate":"2026-03-31"},{"nctId":"NCT07149792","phase":"PHASE4","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-07-29","conditions":["Psoriasis","Psoriasis Arthritis","Biologics"],"enrollment":50,"completionDate":"2028-06-01"},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":["Rheumatic Disease"],"enrollment":80,"completionDate":"2027-09"},{"nctId":"NCT05855967","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-06-27","conditions":["Plaque Psoriasis","Psoriatic Arthritis"],"enrollment":250,"completionDate":"2024-09-23"},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":["Chronic Spontaneous Urticaria (CSU)","Hidradenitis Suppurativa (HS)","Psoriasis (PsO)","Atopic Dermatitis (AD)","CTCL/ Mycosis Fungoides"],"enrollment":840,"completionDate":"2029-12-31"},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":["Psoriasis","Psoriatic Arthritis (PsA)","Cardiovascular Risk Factors","Metabolic Syndrome (MetS)","Drug Survival","Pharmacogenetics"],"enrollment":1000,"completionDate":"2024-06-01"},{"nctId":"NCT06786936","phase":"","title":"Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms","status":"RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2025-06-02","conditions":["Psoriatic Arthritis","Depression","Psoriatic Plaque"],"enrollment":50,"completionDate":"2027-04-30"},{"nctId":"NCT04979910","phase":"PHASE2","title":"Targeting IL-17A for Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-08-27","conditions":["Major Depressive Disorder"],"enrollment":7,"completionDate":"2024-04-12"},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":["Rheumatoid Arthritis","Psoriatic Arthritis","Spondylarthritis"],"enrollment":841,"completionDate":"2024-05-28"},{"nctId":"NCT06374979","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05","conditions":["Guttate Psoriasis"],"enrollment":50,"completionDate":"2026-06"},{"nctId":"NCT06811558","phase":"NA","title":"Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-02-01","conditions":["Over 70-year-old Patients with Psoriasis"],"enrollment":100,"completionDate":"2027-12-31"},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":["Psoriasis","Psoriatic-arthritis"],"enrollment":3500,"completionDate":"2032-12"},{"nctId":"NCT04589325","phase":"PHASE2","title":"Ixekizumab Diabetes Intervention Trial (I-DIT)","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2022-11-09","conditions":["Type1 Diabetes Mellitus"],"enrollment":127,"completionDate":"2027-12"},{"nctId":"NCT04083612","phase":"PHASE4","title":"Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-05-04","conditions":["Psoriasis Vulgaris"],"enrollment":49,"completionDate":"2023-12-31"},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":["Rheumatoid Arthritis","Ankylosing Spondylitis","Psoriatic Arthritis"],"enrollment":10000,"completionDate":"2030-06-30"},{"nctId":"NCT05030415","phase":"EARLY_PHASE1","title":"Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2021-08-12","conditions":["Lichen Planus Scalp","Lichen Planus","Lichen Planopilaris"],"enrollment":9,"completionDate":"2024-03-25"},{"nctId":"NCT03137160","phase":"PHASE2","title":"An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2017-05-04","conditions":["Pyoderma Gangrenosum"],"enrollment":4,"completionDate":"2018-08-16"},{"nctId":"NCT05503875","phase":"NA","title":"Immunoclassification of Psoriasis: a Strategy for Precision Medicine","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-01-01","conditions":["Immunoclassification","Psoriasis"],"enrollment":100,"completionDate":"2027-12-31"},{"nctId":"NCT04102007","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-11-12","conditions":["Plaque Psoriasis"],"enrollment":244,"completionDate":"2022-11-07"},{"nctId":"NCT06085079","phase":"PHASE4","title":"Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study","status":"UNKNOWN","sponsor":"Massachusetts Eye Research and Surgery Institution","startDate":"2022-06-01","conditions":["Uveitis, Posterior","Uveitis, Anterior","Uveitis, Intermediate","Panuveitis"],"enrollment":20,"completionDate":"2024-12-30"},{"nctId":"NCT04285229","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-04-10","conditions":["Spondyloarthritis"],"enrollment":147,"completionDate":"2022-03-17"},{"nctId":"NCT03848403","phase":"PHASE1","title":"Study of Ixekizumab in Healthy Participants","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2019-01-29","conditions":["Healthy"],"enrollment":70,"completionDate":"2019-07-18"},{"nctId":"NCT04537689","phase":"PHASE4","title":"Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis","status":"RECRUITING","sponsor":"Singapore General Hospital","startDate":"2020-12-10","conditions":["Plaque Psoriasis"],"enrollment":40,"completionDate":"2027-12-31"},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":["Psoriatic Arthritis","Withdrawal","Reduction"],"enrollment":270,"completionDate":"2025-10-19"},{"nctId":"NCT04724629","phase":"PHASE3","title":"Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2021-01-05","conditions":["Covid19"],"enrollment":60,"completionDate":"2021-07-30"},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":["Psoriasis"],"enrollment":17743,"completionDate":"2021-03-31"},{"nctId":"NCT03129100","phase":"PHASE3","title":"A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-05-09","conditions":["Axial Spondyloarthritis"],"enrollment":773,"completionDate":"2021-05-27"},{"nctId":"NCT04259346","phase":"PHASE1","title":"A Study of Two Formulations of Ixekizumab in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-05","conditions":["Healthy"],"enrollment":245,"completionDate":"2021-02-19"},{"nctId":"NCT03073200","phase":"PHASE3","title":"Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-03-28","conditions":["Plaque Psoriasis"],"enrollment":201,"completionDate":"2021-03-23"},{"nctId":"NCT05042635","phase":"NA","title":"Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine","status":"UNKNOWN","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2021-10-01","conditions":["Plaque Psoriasis"],"enrollment":90,"completionDate":"2024-09-30"},{"nctId":"NCT03942042","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-07-05","conditions":["Generalized Pustular Psoriasis","Erythrodermic Psoriasis"],"enrollment":12,"completionDate":"2020-07-22"},{"nctId":"NCT03364309","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-04-26","conditions":["Plaque Psoriasis"],"enrollment":438,"completionDate":"2020-06-04"},{"nctId":"NCT03151551","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-08-24","conditions":["Psoriatic Arthritis"],"enrollment":566,"completionDate":"2019-09-04"},{"nctId":"NCT03573323","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-09","conditions":["Plaque Psoriasis"],"enrollment":1027,"completionDate":"2020-01-08"},{"nctId":"NCT01646177","phase":"PHASE3","title":"A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07-28","conditions":["Psoriasis"],"enrollment":1346,"completionDate":"2019-07-22"},{"nctId":"NCT03073213","phase":"PHASE1","title":"A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-04-13","conditions":["Psoriasis"],"enrollment":32,"completionDate":"2019-05-14"},{"nctId":"NCT02349295","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12-31","conditions":["Psoriatic Arthritis"],"enrollment":363,"completionDate":"2019-06-26"},{"nctId":"NCT03485976","phase":"PHASE2","title":"Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2018-05-23","conditions":["Pityriasis Rubra Pilaris"],"enrollment":12,"completionDate":"2020-01-13"},{"nctId":"NCT01597245","phase":"PHASE3","title":"A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-05-18","conditions":["Psoriasis"],"enrollment":1224,"completionDate":"2019-06-18"},{"nctId":"NCT03848416","phase":"PHASE1","title":"A Study of Ixekizumab in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-01-29","conditions":["Healthy"],"enrollment":99,"completionDate":"2019-06-07"},{"nctId":"NCT02513550","phase":"PHASE3","title":"A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-08","conditions":["Plaque Psoriasis"],"enrollment":1257,"completionDate":"2017-08-03"},{"nctId":"NCT02561806","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10","conditions":["Plaque Psoriasis"],"enrollment":302,"completionDate":"2017-10"},{"nctId":"NCT02696798","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-04-12","conditions":["Spondyloarthritis"],"enrollment":316,"completionDate":"2019-05-03"},{"nctId":"NCT03099538","phase":"PHASE2","title":"Ixekizumab in the Treatment of Bullous Pemphigoid","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-08-15","conditions":["Bullous Pemphigoid","Pemphigoid"],"enrollment":4,"completionDate":"2019-06-06"},{"nctId":"NCT04372277","phase":"PHASE4","title":"Taltz in Combination With Enstilar for Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-28","conditions":["Psoriasis"],"enrollment":25,"completionDate":"2021-03-30"},{"nctId":"NCT02757352","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-08-02","conditions":["Axial Spondyloarthritis"],"enrollment":303,"completionDate":"2019-05-07"},{"nctId":"NCT02696785","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05-02","conditions":["Spondyloarthritis"],"enrollment":341,"completionDate":"2018-10-17"},{"nctId":"NCT02584855","phase":"PHASE3","title":"A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-09-14","conditions":["Psoriatic Arthritis"],"enrollment":394,"completionDate":"2018-10-30"},{"nctId":"NCT02634801","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-01-20","conditions":["Plaque Psoriasis"],"enrollment":162,"completionDate":"2017-11-14"},{"nctId":"NCT01474512","phase":"PHASE3","title":"A Phase 3 Study in Participants With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11-16","conditions":["Psoriasis"],"enrollment":1296,"completionDate":"2018-09-20"},{"nctId":"NCT01777191","phase":"PHASE3","title":"Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":["Plaque Psoriasis"],"enrollment":204,"completionDate":"2015-05"},{"nctId":"NCT01107457","phase":"PHASE2","title":"A Study in Participants With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-04","conditions":["Psoriasis"],"enrollment":142,"completionDate":"2016-07"},{"nctId":"NCT02387801","phase":"PHASE3","title":"A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-04","conditions":["Psoriasis"],"enrollment":12,"completionDate":"2016-08"},{"nctId":"NCT02718898","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-04","conditions":["Genital Psoriasis","Psoriasis"],"enrollment":149,"completionDate":"2018-02-21"},{"nctId":"NCT01624233","phase":"PHASE3","title":"A Study in Japanese Participants With Moderate-to-Severe Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-06","conditions":["Psoriasis"],"enrollment":91,"completionDate":"2017-09"},{"nctId":"NCT02993471","phase":"PHASE1","title":"A Study of Ixekizumab in Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-12-22","conditions":["Psoriasis"],"enrollment":28,"completionDate":"2017-11-21"},{"nctId":"NCT01695239","phase":"PHASE3","title":"A Study of Ixekizumab in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":["Psoriasis, Arthritic"],"enrollment":417,"completionDate":"2017-09"},{"nctId":"NCT02543918","phase":"PHASE1","title":"A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-09","conditions":["Healthy"],"enrollment":84,"completionDate":"2015-12"},{"nctId":"NCT00966875","phase":"PHASE2","title":"A Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":["Rheumatoid Arthritis"],"enrollment":448,"completionDate":"2012-06"},{"nctId":"NCT01253265","phase":"PHASE1","title":"A Study in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-05","conditions":["Rheumatoid Arthritis"],"enrollment":32,"completionDate":"2011-12"},{"nctId":"NCT01236118","phase":"PHASE1","title":"A Study of LY2439821 in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":["Rheumatoid Arthritis"],"enrollment":28,"completionDate":"2013-01"},{"nctId":"NCT01870284","phase":"PHASE3","title":"Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2014-07","conditions":["Spondylitis, Ankylosing"],"enrollment":0,"completionDate":"2018-04"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-05-22","unitCost":"$6646.0513/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,392,578","description":"TALTZ 80 MG/ML AUTOINJECTOR","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-03-22T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":"TALTZ","application_number":"BLA125521"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"2392578.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":1},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Taltz","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:58:43.742933+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:59:00.389933+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:58:49.442923+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Taltz","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:58:49.783933+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin 17A inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:58:50.819468+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743034/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:58:50.488176+00:00"}},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:59:00.390088+00:00","fieldsConflicting":1,"overallConfidence":0.8},"crossReferences":{"rxcui":"1745104","chemblId":"CHEMBL1743034","pubchemSID":"187051842"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}